RxDoctor Payments Data

Mary Helen Hutchinson, MD

Dermatology · Greenville, NCNPI 1124040605

Payments from drug & device makers

$4,121in general payments, 2019–2025

Across 276 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • LEO Pharma Inc.$706
  • Pfizer$379
  • Sanofi$274
  • Novartis$135
  • Amgen$123
  • plus $335 from 11 others

What the payments were for

  • Food & beverage$4,02098%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)151$2,169
LEO Pharma Inc.44$706
Pfizer34$379
Sanofi12$274
Novartis9$135
Amgen6$123
E.r. Squibb & Sons, L.L.C.6$99
Johnson & Johnson1$70
Incyte Corporation2$52
Organon4$25
Aclaris Therapeutics, Inc.1$18
DUSA Pharmaceuticals, Inc.1$17
Genentech USA, Inc.1$14
Nabriva Therapeutics, PLC1$14
Regeneron Healthcare Solutions, Inc.1$12
Lilly USA, LLC1$11
Prugen, Inc. Pharmaceuticals1$3

How this compares

$4,121 in reported general payments places this provider in the 60th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,049,364
Medicare patients
1,216
Services billed
10,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab26$262,229
Dupixent PenDupilumab50$197,332
Taltz AutoinjectorIxekizumab13$102,658
OtezlaApremilast15$71,254
OpzeluraRuxolitinib Phosphate14$27,608
Fluorouracil173$12,246
Clobetasol Propionate228$9,561
Mupirocin696$5,190
Tretinoin40$3,784
Triamcinolone Acetonide187$2,195
Betamethasone Dipropionate52$1,868
Doxycycline Monohydrate131$1,595
Acitretin12$1,578
ValacyclovirValacyclovir Hcl85$1,245
Metronidazole29$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$123$71,25415 claims
Incyte CorporationOpzelura$52$27,60814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →